COVID-19 is showing promising antibody results in hundreds of participants in a Phase 2 trial and could be ready for a final authorization request this summer.Nathalie Landry, the executive vice-president for scientific and medical affairs for Medicago, said the vaccine appears to produce 10 times the antibodies as are seen in people who have had COVID-19.“It’s very good news,” said Landry.“So based on these results, let’s say we’re quietly confident that we will be in a position to demonstrate good efficacy of the vaccine.” Medicago begins late-stage study of COVID-19 vaccine with GlaxoSmithKline The results are not yet peer-reviewed but Landry said other vaccines in use showed a direct correlation between the level of antibodies.